Interestingly, the CTG-0012 PDX model was a TNBC stage 4 adenocarcinoma with mutations in BRCA1, ATM, BLM, and p53 (as advertised by Champions Oncology), which are involved in DNA damage repair (DDR). Here, BLM is linked to adenocarcinoma.